Frequent usage of immunoglobulins in medical treatments to boost the immunoglobulin market

calendar_today 25 August, 2022 person_outline Growth Plus Reports

According to the deep-dive market assessment study conducted by Growth Plus Reports, the Global Immunoglobulin Market was pegged at ~US$ 12.4 billion in 2021. The market is expected to witness a CAGR of ~7.1% from 2020 to 2030.

The growth of the global immunoglobulin market is mainly supported by prevalence of immunodeficiency diseases, immunoglobulins are frequently used as treatment, and rising elderly population. The global market for immunoglobulins may be constrained by the high costs of the necessary pharmaceuticals and cases of adverse reactions to immunoglobulins.

In the recent years, the prevalence of immunodeficiency diseases has significantly increased. This rise in the primary immunodeficiency disease such as common variable immunodeficiency (CIVD) is mainly attributed to family history. The immune system is weakened in primary immunodeficiency, making it easier for infections and other health issues to develop. In most PIDs (Primary Immunodeficiency diseases) patients are recommended to use immunoglobulin replacement therapy. In order to raise the antibodies required to protect against infection, it involves receiving blood-based infusions at regular intervals. It can be injected intravenously or subcutaneously. Additionally, immunoglobulins are frequently used for cancer treatment due to the bidirectional relationship between cancer and autoimmunity, the apparent association between cancer regression and immunoglobulin administration, and the fact that immunoglobulins are thought to be a safe medication.

The geriatric population experiences many changes in their immune system such as lack in platelet count, which is associated by acquiring many immunological and neurological diseases. The requirement for frequent and regular platelet transfusions can be reduced by immunoglobulin treatment, which has been demonstrated to increase the platelet count within four days after dosing.

Based on region, the global immunoglobulin market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America has dominated the global immunoglobulin market in the base year 2021. Increased incidence of neurological and immune disorders is the major factor contributing the growth of market in this region. CIDP is an uncommon condition that affects around 40,000 Americans. Its annual incidence is estimated to be between 0.7 and 1.6 cases per 100,000 people, and its total prevalence is between 5 and 9 instances per 100,000 people, with an estimated prevalence of 0.5 cases per 100,000 children. North America is expected to be followed by Asia Pacific in terms of profitable growth during the forecast period. Pharmaceutical firms in this region are investing more in cutting-edge therapies like antibody-drug conjugates, which is predicted to support market expansion in the future years. Additionally, high adoption of immunoglobulins due to rising incidence of immunodeficiency disease is another factor to fuel the growth of the immunoglobulin market in Asia Pacific.

Some of the prominent players operating in the global immunoglobulin market are ADMA Biologics Inc., Baxter International Inc., Biotest AG, Takeda Pharmaceutical Company, CSL Limited, Grifols S.A, Kedrion S.P.A, LFB S.A, Octapharma AG, Pfizer Inc., and Bayer Healthcare Pharmaceuticals LLC among others.

This report entails a thorough quantitative analysis of the trends from 2022 to 2030 in the immunoglobulin market The global immunoglobulin market has been analyzed from four perspectives: by products, applications, route of administration, and region. The product segment is further divided into Immunoglobulin G (IgG), Immunoglobulin (IgA), Immunoglobulin M (IgM), Immunoglobulin E (IgE), and Immunoglobulin D (IgD). The application segment is further grouped into hypo gamma globulin, Chronic Inflammatory Demyelinating Polyneuropathy, immunodeficiency diseases and myasthenia gravis. By route of administration the global immunoglobulin market is grouped into intravenous, and subcutaneous.

awards awards key differentiators

Reach Us

Web –

// // // //